Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of CVM-1118 Plus Sintilimab and TACE for Unresectable Hepatocellular Carcinoma
ChiCTR2600122789Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib and sintilimab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate (ORR, RECIST 1.1). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
dasatinibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600122789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122789.